Crestor to be divested to Grünenthal in Europe

AstraZeneca has agreed to sell the rights to Crestor(rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal GmbH (Grünenthal). Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia.
Läs mer